No categories for this tab

About Us

About PharmaCountry
How It Works
Partnerships
Sustainability
Contact Us

For Buyers

Search Products
Search Services
Find Suppliers
Find Jobs
Find Seekers
Help Center
FAQ
Buyer Protection

For Sellers/Service Providers

Start Selling
Seller Guide
Pricing Plans
Advertising
Seller Support

Top Categories

Active Pharmaceutical Ingredients (APIs)
Finished Dosage Forms
Manufacturing Equipment & Utilities
Excipients & Additives
View All Categories

Stay Connected

[email protected]

24/7 Customer Support

Trusted B2B Platform

SSL Secure Transactions Verified Suppliers Quality Assured B2B Certified Global Network

© 2026 PharmaCountry. All rights reserved.

Privacy Policy Terms of Service Cookie Policy

Products
Finished Dosage Forms
Tablets
Immediate-Release Tablets

듀비엠폴서방정0.25/12.5/1000밀리그램(로베글리타존,엠파글리플로진,메트포르민)

(주

Marketing Authorization Holder · Finished Dosage FormsRepublic of Korea

Basic Information

Category

Subcategory & Sub-subcategory

/

Trade Type

Sell

Product Name

듀비엠폴서방정0.25/12.5/1000밀리그램(로베글리타존,엠파글리플로진,메트포르민)

Details

• •

Substance

• •

Registered Market

Specifications

Dosage Form: Extended-release tablet

Documents

Drug Marketing Authorization Number

Document No.: 5434

Issue Date: Mar 10, 2026

Ratings

(0)

(0)

(0)

(0)

(0)

Leave your rating & comment

Comments

Filters:

Sort by:

No comments available.

Matched Products & Services

B2B matches based on trade type, category, specifications & price range

Similar Products & Services

Products & Services related to what you're viewing

People Also Viewed

Other products & services viewed by people who looked at this product

Finished Dosage Forms

Immediate-Release Tablets

Empagliflozin L-Proline

Lobeglitazone Sulfate

Metformin hydrochloride

Empagliflozin L-Proline

Lobeglitazone sulfate

Metformin Hydrochloride

Republic of Korea

듀비엠폴서방정0.25/12.5/1000밀리그램(로베글리타존,엠파글리플로진,메트포르민) | Pharmacountry